← Back to Clinical Trials
Recruiting NCT06532981

NCT06532981 The Effect of AFOs on the EMG of Children With CP

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT06532981
Status Recruiting
Phase
Sponsor Universitaire Ziekenhuizen KU Leuven
Condition Spastic Cerebral Palsy
Study Type OBSERVATIONAL
Enrollment 30 participants
Start Date 2023-01-06
Primary Completion 2026-12-31

Eligibility & Interventions

Sex All sexes
Min Age 6 Years
Max Age 17 Years
Study Type OBSERVATIONAL

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.

This trial targets 30 participants in total. It began in 2023-01-06 with a primary completion date of 2026-12-31.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

Children with cerebral palsy (CP) have altered gait patterns as a result of primary and secondary symptoms. Ankle-foot orthoses (AFOs) are frequently used to improve their gait. Despite evidence of AFO-effects on gait kinetics and -kinematics, the effects on muscle activity remain unclear. This study will investigate the effect of AFOs on the amplitude and timing, as well as the co-activation of lower limb muscle activity in children with spastic CP.

Eligibility Criteria

Inclusion criteria: * Gross Motor Function Classification System (GMFCS) level I - III * CP (bilateral \& unilateral) * Age: 6 - 17 years * Prescribed AFO by the medical team (as part of the standard care) Exclusion criteria: * Severe contractures or spasticity, which makes it impossible to wear a conventional AFO * Cognitive or visual impairment that hinder them to understand instructions * Previous surgery on bones and/or muscles of the legs in the last 12 months prior to assessment * Presence of ataxia or dystonia

Contact & Investigator

Central Contact

Laure Everaert

✉ laure.everaert@kuleuven.be

📞 +32472277564

Principal Investigator

Kaat Desloovere, Prof. dr.

PRINCIPAL INVESTIGATOR

Department of Rehabilitation Sciences, KU Leuven, Belgium

Frequently Asked Questions

Who can join the NCT06532981 clinical trial?

This trial is open to participants of all sexes, aged 6 Years or older, up to 17 Years, studying Spastic Cerebral Palsy. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT06532981 currently recruiting?

Yes, NCT06532981 is actively recruiting participants. Contact the research team at laure.everaert@kuleuven.be for enrollment information.

Where is the NCT06532981 trial being conducted?

This trial is being conducted at Leuven, Belgium.

Who is sponsoring the NCT06532981 clinical trial?

NCT06532981 is sponsored by Universitaire Ziekenhuizen KU Leuven. The principal investigator is Kaat Desloovere, Prof. dr. at Department of Rehabilitation Sciences, KU Leuven, Belgium. The trial plans to enroll 30 participants.

Related Trials

Related Intelligence Guides

In-depth guides covering this condition's trials, eligibility, and what to expect.

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: September 2026  ·  Data Methodology